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A B S T R A C T
The proviral integration site for Moloney murine leukemia virus (PIM) family of serine/threonine-specific ki-
nases consist of three isoforms, that regulate proliferation, apoptosis, metabolism, invasion, and metastasis of
cancer cells. Among these, abnormally elevated kinase activity of PIM-1 contributes to the progression of gastric
cancer and predicts poor prognosis and a low survival rate in gastric cancer patients. In the present study, we
found that resveratrol, one of the representative chemopreventive and anticarcinogenic phytochemicals, directly
binds to PIM-1 and thereby inhibits its catalytic activity in human gastric cancer SNU-601 cells. This resulted in
suppression of phosphorylation of the proapoptotic Bad, a known substrate of PIM-1. Resveratrol, by inactivating
PIM-1, also inhibited anchorage-independent growth and proliferation of SNU-601 cells. To understand the
molecular interaction between resveratrol and PIM-1, we conducted docking simulation and found that re-
sveratrol directly binds to the PIM-1 at the ATP-binding pocket. In conclusion, the proapototic and anti-pro-
liferative effects of resveratrol in gastric cancer cells are likely to be mediated through suppression of PIM-1
kinase activity, which may represent a novel mechanism underlying its chemopreventive and anticarcinogenic
actions.
1. Introduction
Gastric cancer is the fourth most common malignancy, substantially
contributing to cancer-related mortality in many countries [1]. In
Korea, gastric cancer was the most commonly diagnosed cancer in 2016
[2], and is predicted to be the second prevalent in men in 2019 [3]. As
molecular and genetic alterations are complex in the pathogenesis of
gastric cancer, it is still difficult to make an early diagnosis, and most of
the patients are diagnosed at advanced stages. Despite the improvement
in the treatment of gastric cancer such as surgery, chemotherapy and
radiotherapy, these conventional therapies have limited efficacy in re-
ducing the mortality of this malignancy [4].
Over the past decades, there has been increasing interest in identi-
fying phytochemicals that can prevent or halt carcinogenic processes. As
conventional cancer therapy causes substantial adverse effects, one of the
most promising approaches to reduce the burden of gastric cancer is
considered to be the use of chemopreventive agents [5]. It has been re-
ported that intake of dietary chemopreventives contributes to a reduction
in the cancer incidence by suppressing multiple oncogenic events [6,7].
Resveratrol (trans-3,4′,5-trihydroxystilbene) was first isolated from the
roots of Veratrum grandiflorum O. Loes (white hellebore) and is abundant
in red wine, grapes, berries, peanuts, and more than 70 other plant
species [8]. Resveratrol has been extensively investigated for its che-
mopreventive and chemotherapeutic potential [9,10]. This
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phytochemical is well known for its inhibitory effects on the growth and
proliferation of many different types of cancer cells [11–14].
Recently, the serine/threonine family of proviral integration site for
Moloney murine leukemia virus (PIM) kinases have emerged as new
targets for cancer therapy. PIM kinases are evolutionarily conserved
and composed of PIM-1, PIM-2 and PIM-3 isoforms. Of these, PIM-1 is
overexpressed in hematologic and solid tumors and implicated in their
pathogenesis.
PIM-1 is involved in cancer cell cycle regulation [15], survival [16],
drug resistance [17–19], and Myc-related tumorigenicity [20,21]. Most
representative cellular substrates of PIM-1 include p21WAF1 [22,23],
Bad [24], and mouse double minutes 2 homolog (Mdm2) [25] which
are regulators of apoptosis and cell cycle progression. One of the
mediators of cytokine signaling responsible for regulating PIM-1 ex-
pression is STAT3. STAT3 can bind directly to the ISFR/GAS-sequence
of the PIM-1 promoter [26]. Overexpression of PIM-1 has been asso-
ciated with poor survival in many different types of malignancies in-
cluding gastric cancer [27], suggesting its potential as a prognostic and
therapeutic target [28,29].
In the present study, we investigated the effects of resveratrol on
proliferation, invasiveness, and survival of gastric cancer cells with
PIM-1 as a potential target.
2. Materials and methods
2.1. Reagents and antibodies
Resveratrol (5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol)
was purchased from Cayman Chemicals (Ann Arbor, MI, USA). Roswell
Park Memorial Institute (RPMI) 1640 Medium and fetal bovine serum
(FBS) were obtained from Gibco BRL (Grand Island, NY, USA). Primary
antibodies for PIM-1 and β-actin were supplied by Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Primary antibodies for PIM-1,
caspase-3, cleaved caspase-3, poly(ADP-ribose) polymerase (PARP),
Bcl-2-associated death promoter (Bad), phospho (Ser112)-Bad (P-Bad)
and cleaved PARP were supplied by Cell Signaling Technology
(Danvers, MA, USA). PIM-1 siRNA (5′- CCGGTGCAAGATCTCTTCGAC
TTCA -3′) and RNAi negative control duplexes were purchased from
Genolution Pharmaceuticals, Inc. (Seoul, South Korea). MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The bi-
cinchoninic acid (BCA) protein assay reagent was a product of Pierce
Biotechnology (Rockfold, IL, USA). Polyvinylidene difluoride (PVDF)
membrane was supplied from Gelman Laboratory (Ann Arbor, MI,
USA). Adenosine 5′-triphosphate (ATP) was supplied by New England
Biolabs (Ipswich, MA, USA). RNAi-MAX and Lipofectamine 3000 were
products of Invitrogen (Carlsbad, CA, USA).
2.2. Cell culture
SNU-216, SNU-484, SNU-601, SNU-638, and SNU-668 cell lines
were purchased from the Korean Cell Line Bank (http://cellbank.snu.
ac.kr). The cells were cultured in monolayers by using RPMI 1640
supplemented with 10% FBS and 1% antibiotic-antimycotic. Cells were
maintained in a 37 °C in humidified incubator ventilated with 5% CO2
and 95% air.
2.3. Transient transfection with small interfering RNA (siRNA) or
overexpression vector
Cells at a confluence of 60–70% were transfected with control
siRNA (40 nM) or PIM-1 siRNA (40 nM) with Lipofectamine RNAi-MAX
reagent according to the manufacturer's instructions. For over-
expression of PIM-1, cells were transfected with a plasmid carrying
cDNA for PIM-1 using Lipofectamine reagent. The transfection was
conducted according to the manufacturer's instructions. An empty
vector was used as a control.
2.4. Cell proliferation assay
Cells were cultured for 96 h in the presence of various concentra-
tions of resveratrol dissolved in DMSO. Cells were then treated with the
MTT reagent dissolved in phosphate-buffered saline (PBS) at a final
concentration of 0.5 mg/ml for additional 4 h. After medium was re-
moved, DMSO was added to dissolve the formazan crystal, and the
absorbance at 570 nm was read.
2.5. Anchorage-independent growth assay
The anchorage-independent cell transformation assay was per-
formed in SNU-601 cells. Briefly, cells (8 × 103 cells/well) suspended
in RPMI1640 media containing 10% FBS were added to 0.3% agar with
or without indicated concentrations of resveratrol. The cultures were
maintained at 37 °C in a 5% CO2 incubator for 2 weeks, and the cell
colonies were scored using an ECLIPSE Ti inverted microscope and the
NIS-Elements AR (V. 4.0) computer software program (NIKON
Instruments Korea, Seoul, Korea).
2.6. Clonogenic assay
Cells were plated (5 x 102 cells/well) in 6-well culture plates. After
7–10 days, the cells were fixed in cold ethanol for 30 min and stained by
0.5% crystal violet for 30 min. Stained cells were rinsed by tap water
and dried in room temperature.
2.7. Western blot analysis
Cells were gently washed with cold PBS, scraped, and centrifuged at
15,000 g for 5 min. Pellets were suspended in lysis buffer and subjected
to repeated freezing and thawing three times, followed by centrifuga-
tion at 20,000 g for 15 min. Supernatant was collected as a whole cell
lysate. The protein concentration of whole cell lysate was determined
by using a BCA protein assay kit. Protein samples from whole cell ly-
sates were mixed with sodium dodecyl sulfate (SDS) sample loading dye
and boiled at 99 °C for 5 min. Protein samples were electrophoresed on
SDS-polyacrylamide gel and transferred to PVDF membranes. The blots
were then blocked with 5% fat-free dry milk-TBST (Tris-based saline
containing 0.1% Tween-20) buffer for 1 h at room temperature. The
blots were incubated with primary antibodies in TBST. Following three
washes with TBST, the blots were incubated with rabbit or mouse
secondary antibody in 3% fat-free dry milk-TBST for 1 h at room
temperature. The blots were rinsed again three times with TBST, and
the transferred proteins were incubated with the ECL substrate detec-
tion reagent for 1 min, according to the manufacturer's instructions and
visualized with LAS 4000.
2.8. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from cells by using TRIzol® (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's protocol. To gen-
erate cDNA, 1 μg of total RNA was reverse transcribed with Moloney
murine leukemia virus reverse transcriptase (Promega; Madison, WI,
USA) for 50 min at 42 °C and again for 15 min at 72 °C. One μl of cDNA
was amplified in sequential reactions using Maxtime PCR PreMix Kit
(iNtRON Biotechnology; Seongnam, South Korea). The mRNA expres-
sion of PIM-1 (28 cycles of 94 °C for 30 s, 48 °C for 30 s, and 72 °C for
30 s) and GAPDH (20 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C
for 30 s) was measured. These PCR cycles were followed by final ex-
tension for 7 min at 72 °C. The primers used for each RT-PCR reactions
are as follows (forward and reverse, respectively): PIM-1, 5′-ATC CTT
ATC GAC CTC AAT CG-3′ and 5′-TGA TGA TCT CTT CGT CAT GC -3’;
GAPDH, 5′-CCG AGA TGG GGT TGA TAA TG -3′ and 5′-ACA GTG GCC
S. Kim, et al. Archives of Biochemistry and Biophysics 689 (2020) 108413
2
ACC TAC AAA GG -3’. Amplification products were resolved by 2.0%
agarose gel electrophoresis, stained with ethidium bromide, and pho-
tographed under ultraviolet light.
2.9. Annexin Ⅴ and propidium iodide (PI) staining
Cells were washed with cold PBS and centrifuged at 1,500 g for
4 min three times. Supernatant was aspirated, and the cells were re-
suspended in 1 ml of 1x Annexin Ⅴ binding buffer. Five μl of Annexin
Ⅴ-FITC and 5 μl of PI were added to the cells and incubated for
15 min at room temperature in the dark. After addition of 1x binding
buffer, the cells were analyzed by FACS caliber.
2.10. Immunocytochemistry
Cells were rinsed with PBS and fixed for 10 min at 4 °C with 5%
acetic acid in methanol, followed by blocking with 5% bovine serum
albumin (BSA) in PBS for 30 min in room temperature. Cells were in-
cubated with PIM-1 antibody diluted 1:200 in blocking buffer at 4 °C.
After washing with PBS, the cells were incubated with FITC conjugated
anti-rabbit immunoglobulin G (IgG) secondary antibody diluted at
1:1,000 for 1 h and examined under a fluorescence microscope.
2.11. Affinity chromatography and pull-down assay
CNBr-activated Sepharose™ 4B was obtained from GE Healthcare
(Little Chalfont, UK). Resveratrol-conjugated Sepharose 4B beads were
prepared according to the protocol described by Urusova et al. [30].
Cells were lysed by using lysis buffer [50 mM Tris-HCl, pH 7.5, 5 mM
EDTA, 150 mM NaCl, 1 mM dithiothreitol (DTT), 0.01% Nonidet P-40,
0.02 mM phenylmethylsufonylfluoride (PMSF), and 1x protease in-
hibitor mixture]. After centrifugation at 15,000 g, the resulting super-
natant (500 μg) was mixed with resveratrol-Sepharose 4B beads or
Sepharose 4B beads alone as a control in reaction buffer [50 mM Tris-
HCl (pH 7.5), 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% Nonidet P-
40, 2 mg/ml BSA, 0.02 mM PMSF, and 1x protease inhibitor mixture].
After overnight incubation in a rotator at 4 °C, the samples were rinsed
five times with washing buffer [50 mM Tris-HCl (pH 7.5), 5 mM EDTA,
150 mM NaCl, 1 mM DTT, 0.01% Nonidet P-40, and 0.02 mM PMSF]
and subjected to Western blot analysis. Proteins bound to the beads
were analyzed by immunoblotting with anti-PIM-1 antibody.
2.12. Kinase assay
The catalytic activity of PIM-1 was measured by using PIM-1
KINOMEscan™ platform which is a comprehensive high-throughput
system. For most assays, kinase-tagged T7 phage strains were prepared
in an E. coli host derived from the BL21 strain. E. coli were grown to log-
phase, infected with T7 phage, and incubated with shaking at 32 °C
until lysis. The lysates were centrifuged and filtered to remove cell
debris. The remaining kinase was produced in HEK-293 cells and sub-
sequently tagged with DNA for qPCR detection. Streptavidin-coated
magnetic beads were treated with biotinylated resveratrol for 30 min at
room temperature to generate affinity resins for the kinase assay. The
liganded beads were blocked with excess biotin and washed with SEA
BLOCK blocking buffer (1% BSA, 0.05% Tween 20, and 1 mM DTT) to
reduce nonspecific binding. Binding reactions were assembled by
combining kinases, liganded affinity beads, and test compounds in 1x
binding buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM
DTT). All reactions were performed in polystyrene 96-well plates in a
final volume of 0.135 ml. The assay plates were incubated at room
temperature with shaking for 1 h, and the affinity beads were rinsed
with wash buffer (1x PBS, 0.05% Tween 20). The beads were then re-
suspended in elution buffer (1x PBS, 0.05% Tween 20, 0.5 μM non-
biotinylated affinity ligand) and incubated at room temperature with
shaking for 30 min. The kinase concentration in the eluates was
measured by qPCR.
2.13. Docking simulation
AutoDock Vina program [31] (The Scripps Research Institute; La
Jolla, CA, USA) was used in the docking studies. Initial structures of
ligand-free PIM-1 and AMPPNP-bound PIM-1 [32] were obtained from
the Protein Data Bank (PDB) (PDB ID: 1XQZ and PDB ID: 1XR1, re-
spectively), and coordinates for the resveratrol were generated using
the GlycoBioChem PRODRG2 Server (http://davapc1.bioch.dundee.ac.
uk/prodrg/). The grid maps for docking studies were centered on the
ATP binding pocket and comprised 60 X 60 X 60 points with 1.0 Å
spacing after AMPPNP was removed from the complex structure. The
AutoDock Vina program was run with eight-way multithreading and
the other parameters were default settings in the AutoDock Vina pro-
gram.
2.14. Statistical analysis
When necessary, data were expressed as means of ± SD of at least
three independent experiments, and statistical analysis for single com-
parison was performed using the Student's t-test. The criterion for sta-
tistical significance was *p < 0.05, **p < 0.01 and ***p < 0.001.
3. Results
3.1. PIM-1 is overexpressed in gastric cancer patients and cell lines
We first examined the prognostic significance of the expression level
of each of three PIM kinase isoforms using the public dataset. Kaplan-
Meier plotter analysis revealed the correlation between expression le-
vels of PIM-1 and prognosis of gastric cancer. The probabilities of
overall survival among patients with gastric cancer were significantly
reduced with an increased PIM-1 transcript level (Fig. 1A left panel).
Higher PIM-1 expression was also associated with a shorter time to first
progression in gastric cancer patients (Fig. 1A right panel). There was
less prominent association between PIM-2 expression and overall sur-
vival or time to first progression (Fig. 1B). For PIM-3, the high tran-
script levels had opposite effects, compared with PIM-1 (Fig. 1C). Based
on these observations, we focused on PIM-1 in the subsequent studies.
Next, we checked the expression levels of PIM-1 in various gastric
cancer cell lines. We examined the PIM-1 expression in five different
SNU gastric cancer cell lines which were established from Korean
cancer patients. SNU-216 and SNU-601 express relatively higher levels
of PIM-1 than the other three (SNU-484, SNU-638 and SNU-668) cell
lines (Fig. 2A). The SNU-601 cell line was selected to evaluate the
subcellular localization of PIM-1 by immunocytochemistry. As illu-
strated in Fig. 2B, PIM-1 was found to be predominantly localized in
nucleus, which is consistent with the previous observation [33]. Ectopic
overexpression of PIM-1 in SNU-668 cells that exhibit a relatively low
basal level of PIM-1 expression resulted in a significant increase in the
proliferation of gastric cancer cells (Fig. 2C). In contrast, knockdown of
PIM-1 markedly reduced the cell viability compared with control
(Fig. 2D). PIM-1 silencing in SNU-601 cells also suppressed colony
formation as determined by the clonogenic assay (Fig. 2E). We also
assessed the effect of PIM-1 knockdown on apoptosis by differential
staining of cells with Annexin V and PI followed by flow cytometric
analysis. The proportion of apoptotic cells increased markedly (Fig. 2F),
as reflected by cleavage of caspase-3 and PARP, hallmarks of apoptosis
(Fig. 2G). Thus, it is evident that PIM-1 contributes cell proliferation
and survival of SNU-601 cells.
3.2. Resveratrol suppresses gastric cancer cell proliferation
Treatment of SNU-216, SNU-601 and SNU-668 cells with resveratrol
(25, 50 and 100 μM) resulted in decreased cell proliferation in a
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concentration-dependent manner. The IC50 values of resveratrol in in-
hibiting the proliferation of these cell lines were 55.41 μM, 30.14 μM
and 87.17 μM, respectively. Interestingly, SNU-668 gastric cancer cells
with low basal PIM-1 expression were less susceptible to the anti-pro-
liferative effect of resveratrol (Fig. 3A), compared with the other two
cell lines expressing higher level of PIM-1. This finding suggests that the
anti-cancer effect of resveratrol can be mediated, at least in part, by
targeting PIM-1.
Resveratrol also caused concentration-dependent inhibition of
colony formation (Fig. 3B) and anchorage-independent growth
(Fig. 3C) of SNU-601 cells. Moreover, resveratrol treatment resulted in
the increased proportion of apoptotic cells (Fig. 4A) and cleavage of
caspase-3 and PARP (Fig. 4B). Bad, a prototypic pro-apoptotic protein,
is one of the major substrates of PIM-1. Under the same experimental
Fig. 1. Overexpression of PIM-1 in human gastric cancer and its implication for tumor growth and progression. Kaplan-Meier analysis of median overall survival time
(left) and time to first progression (right) of patients with gastric cancer, stratified by the mRNA expression levels of three PIM isoforms based on 209193_at (A),
204269_at (B) and 224739_at (C) probes. Source: Kaplan-Meier plotter database (http://www.kmplot.com).
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conditions, the inactivation of Bad through phosphorylation at Ser112
was repressed (Fig. 4C). Taken together, these data suggest that re-
sveratrol inhibits proliferation of SNU-601 gastric cancer cells, possibly
by targeting PIM-1.
3.3. Resveratrol inhibits catalytic activity, but not expression of PIM-1
In the next experiment, we examined the effect of resveratrol on
PIM-1 expression. The mRNA (Fig. 4D, F) and protein (Fig. 4E, G) levels
of PIM-1 did not show marked differences with and without resveratrol
treatment in SNU-601 cells. Then, we determined the effects of re-
sveratrol on catalytic activity of PIM-1 based on a competition assay.
The principle of this assay is schematically represented in Fig. 5A. As
illustrated in Fig. 5B, resveratrol inhibited the kinase activity of PIM-1
in a concentration-dependent manner. We speculated that resveratrol
may inactivate PIM-1 through structural modification. To verify
Fig. 2. Effects of PIM-1 on viability, survival, and invasiveness of human gastric cancer cells. (A) Basal levels of PIM-1 protein expression were measured by Western
blot analysis in different human gastric cancer cell lines. (B) Subcellular localization of PIM-1 in the SNU-601 cell line determined by immunocytochemistry. (C) After
24 h of seeding in a 48-well plate, SNU-668 cells were transfected with empty pCS4 plasmid (Control) or pCS-PIM-1. Cell viability was measured by the MTT assay
96 h after transfection. Data represent mean ± SD (n = 3); ***Significantly different from the control (p < 0.001). (D) SNU-601 cells were seeded into 48-well
plates. After 24 h of incubation, cells were transfected with PIM-1 siRNA (5 nM and 40 nM) or non-specific siRNA, and the cell viability was measured by the MTT
assay. Data represent mean ± SD (n = 3); ***Significantly different from the control (p < 0.001). (E) SNU-601 cells were seeded into 6-well plates at a density of
0.5 × 104 per well. Next day, PIM-1 siRNA and non-specific siRNA were transfected. After 2 weeks, cells were stained by 0.5% crystal violet. Data represent
mean ± SD (n = 3); **Significantly different from the control (p < 0.01). (F) SNU-601 cells were transfected with PIM-1 siRNA for 72 h and harvested.
Representative flow cytometric dot plots represent changes in the proportion of apototic cells. (G) Immunoblotting was conducted using apoptotic marker antibodies
in PIM-1 silenced and control cells.
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physical interaction between PIM-1 and resveratrol in SNU-601 cancer
cells, the Sepharose 4B assay was performed (Fig. 5C). Whole lysate of
SNU-601 cells was precipitated with resveratrol-conjugated Sepharose
4B beads, suggesting that resveratrol directly binds to PIM-1 (Fig. 5D).
3.4. Resveratrol interacts with PIM-1 kinase at the ATP-binding site
To gain further insights into the molecular interaction between re-
sveratrol and PIM-1, docking experiments were implemented with focus
on identification of the binding site of resveratrol. The structures of
ligand-free PIM-1 and AMPPNP-bound PIM-1 were selected as docking
Fig. 3. Resveratrol inhibits cell proliferation and growth of human gastric cancer cells. (A) SNU-216, SNU-601 and SNU-668 cells were seeded in 96-well plates. After
24 h of incubation, cells were treated with resveratrol (0, 25, 50 and 100 μM) for 96 h. Cell viability was measured by the MTT assay. The 50% inhibitory
concentration of cell proliferation in SNU-216, SNU-601 and SNU-668 were 55.41 μM, 30.14 μM, 87.17 μM, respectively. The asterisks indicate differences between
untreated and resveratrol treated groups. Data represent mean ± SD (n = 3) (**p < 0.01 and ***p < 0.001). (B) SNU-601 cells were seeded and after 24 h, cells
were treated with resveratrol (0, 25, 50 and 100 μM) for 2 weeks. (C) The 6-well plate was coated with 0.3% bottom agar with resveratrol, and SNU-601 cells were
suspended with 0.3% top agar at the density of 8 × 103 cells per well. After 2 weeks, the cell colonies were scored using an ECLIPSE Ti inverted microscope and the
NIS-Elements AR (V. 4.0) computer software program. Data represent mean ± SD (n = 3). ***Significantly different from the control (p < 0.001).
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templates because their crystal structures showed a significant differ-
ence in a loop enveloping the active site (Fig. 6A). Control docking
experiments were implemented with AMPPNP to the crystal structures
of PIM-1 in complex with AMPPNP (PDB ID: 1XR1) after removal of the
AMPPNP, which exhibited the correct binding mode of AMPPNP at the
ATP-binding pocket of PIM-1 with stabilization energy of −7.0 kcal/
mol (data not shown). The docking experiments executed with resver-
atrol revealed that the molecule occupies the ATP-binding pockets of
both ligand-free PIM-1 and AMPPNP-bound PIM-1 with stabilization
energies of −7.9 kcal/mol and −7.1 kcal/mol, respectively (Fig. 6Ba
and b). These data suggest that resveratrol is capable of occupying the
PIM-1 ATP-binding pocket.
Fig. 4. Resveratrol induces apoptosis and activates apoptotic signaling in gastric cancer cells. (A) SNU-601 cells were seeded into 6-well plates and treated with
resveratrol (50 μM) for 48 h. After staining with PI and Annexin, cells were analyzed by the FACS Calibur Flow Cytometer. Red box and blue boxes represent late and
early apoptotic cells, respectively. Data represent mean ± SD (n = 3) (***p< 0.001). (B) Whole lysates from SNU-601 cells treated with resveratrol (50 μM) for 48 h
were subjected to Western blot analysis. Data represent mean ± SD (n = 3). ***Significantly different from the control (p< 0.001). (C) After treatment with 50 μM
of resveratrol, the expression levels of Bad and its phosphorylated form (P-Bad) in SNU-601 cells were measured by Western blot analysis. Data represent mean ± SD
(n = 3). ***Significantly different from the control (p< 0.001). (D and E) SNU-601 cells were treated with 50 μM of resveratrol for 12 h and 24 h. The expression of
PIM-1 mRNA (D) and its protein product (E) was determined by semi-quantitative RT-PCR and Western blot analyses, respectively. (F and G) After treatment with
resveratrol (25 or 50 μM) for 24 h, mRNA (F) and protein (G) expression of PIM-1 was measured as described above. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web version of this article.)
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4. Discussion
Kinases have been considered as a potential target for anti-cancer
therapy as they are frequently mutated in many different types of
human tumors [34,35]. PIM-1 has attracted much attention for the anti-
cancer drug development. In a wide range of human tumors of both
hematopoietic and epithelial origin, PIM-1 kinase is frequently over-
expressed. Especially, constitutive overexpression of PIM-1 in gastric
tumor is associated with poor prognosis and a low survival rate of
cancer patients [36,37]. Therefore, many attempts have been made to
discover molecular inhibitors of this enzyme. Nevertheless, some ob-
stacles, such as drug toxicity and safety, have hampered the
development of the effective PIM-1 inhibitors for use in cancer therapy
[33]. In this study, we found that the catalytic activity of PIM-1 was
inhibited by resveratrol treatment. Notably, resveratrol inhibited pro-
liferation and survival of gastric cancer cells more efficiently in PIM-1
overexpressing cells. These effects of resveratrol mimick those achieved
by PIM-1 silencing.
Resveratrol has been extensively investigated with regards to its
suppressive effect on cancer and inflammation. Resveratrol inhibits Src
and STAT3 signaling in malignant cells, resulting in cell cycle arrest and
loss of viability [38]. It also suppresses constitutively active NF-κB
through inhibition of IκBα kinase, phosphorylation of IκBα and p65, etc
[13]. In another study, resveratrol blocked the ubiquitination of NEMO
Fig. 5. Resveratrol covalently binds to PIM-1 and inhibits its kinase activity. (A) The catalytic activity of PIM-1 was determined based on a competition assay
(DiscoveRX screen system) that quantitatively measures the ability of a compound to compete with an immobilized, active-site directed ligand. The assay system
consists of three components: DNA-tagged kinase, immobilized ligand, and a test compound. The ability of the test compound to compete with the immobilized
ligand was measured via quantitative PCR of the DNA tag. (B) Effects of resveratrol on PIM-1 kinase activity. Data represent the average value of two independent
experiments, and the half maximal inhibitory concentration of resveratrol was calculated as 1.4 μM. (C) Whole-cell lysates from SNU-601 cells were incubated with
resveratrol-Sepharose 4B beads. The PIM-1 bound to the resveratrol conjugated Sepharose 4B beads was pulled down by centrifugation and analyzed by Western blot
analysis using antibody against PIM-1. (D) Lane 1 represents the input control and lane 2, a negative control in which the cell lysates were precipitated with
Sepharose 4B beads only. In lane 3, SNU-601 cell lysates were precipitated using resveratrol conjugated to Sepharose 4B beads.
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and inhibited IκB kinase β-mediated NF-κB activation [14]. We specu-
lated that suppression of upstream signaling which regulates PIM-1
expression and direct inhibition of PIM-1 may provoke a synergistic
effect on growth and progression of gastric cancer. However, PIM-1
expression was unchanged by resveratrol despite its inhibitory effects
on STAT3 and NF-κB signaling.
PIM-1 utilizes many kinds of cellular substrates which are involved
in regulating cell cycle, apoptosis, cell metabolism, etc. Examples are c-
Myc, p21WAF1/CIP1, Mdm2, and Bad [39]. PIM-1 forms a complex with
Myc and Myc-associated factor X (MAX), and phosphorylates Ser10 of
histone H3 on the nucleosome. This increases transcriptional activity of
Myc [20,21]. PIM-1 also phosphorylates Thr145 of p21WAF1/CIP1,
thereby decreasing stability and nuclear translocation of this cell cycle
inhibitory protein [22,23]. Furthermore, phosphorylation of Mdm2 by
PIM-1 at Ser166 and Ser186 increases the ability of Mdm2 to interact
with its inhibitor, ARF. This blocks the degradation of Mdm2, leading to
accumulation of the tumor suppressor p53 [25]. As a result, senescence-
associated β-galactosidase accumulates [25]. Phosphorylation of Bad at
Ser112 facilitates proteasomal degradation of this pro-apoptotic protein
[24]. Because Bad is directly phosphorylated by PIM-1, we measured
the phosphorylation level of Bad in the absence and presence of re-
sveratrol. Resveratrol treatment inhibited the phosphorylation of Bad
without altering the expression level of total Bad in SNU-601 gastric
cancer cells.
Because PIM-1 is overexpressed in many cancers and involved in
cancer specific pathways, it represents a potential target for anti-cancer
drug development [33]. The most prominent inhibitor of PIM-1 is SGI-
1776 which suppresses all PIM kinase family members at low con-
centrations by occupying the ATP binding site. SGI-1776 induces G1
arrest and apoptosis and thereby it reduces cancer cell viability and
their chemo-resistance [39,40]. Nevertheless, the clinical development
of PIM-1 inhibitors has been failed due to side effects, such as cardiac
toxicity [41]. Thus, natural compounds are preferred to synthesized
pharmaceuticals because of their relatively low side effects and toxicity.
In this context, resveratrol derived from red wine, grapes, berries and
peanuts may have a potential as a clinically relevant PIM-1 inhibitor.
In summary, our study provides new insights into the molecular
mechanisms responsible for the anti-tumor effect of resveratrol (Fig. 7).
Resveratrol inhibits PIM-1 activity through direct binding, thereby
regulating the functional activities of PIM-1 substrate molecules. This
account for its inhibitory effects on gastric cancer cell growth and
proliferation. Multiple sequence alignment of PIM-1, PIM-2, and PIM-3
using Clustal Omega displayed with ESPript 3.0 (http://espript.ibcp.fr)
shows that PIM-1, PIM-2, and PIM-3 share high sequence identity
(53.75% between PIM-1 and PIM-2, and 66.77% between PIM-1 and
PIM-3) (Supplementary Fig. 1). Indeed, the structures of ligand-free
PIM-1 and 3 YR-bound PIM-2 were highly similar over 217 equivalent
Cα atoms with a root-mean-square deviation (RMSD) of 1.02 Å.
Fig. 6. Resveratrol binds to the PIM-1 ATP-binding pocket. (A) Cartoon representation of ligand-free PIM-1 (green) and a loop region of AMPPNP-bound PIM-1
showing a conformational change upon AMPPNP binding (magenta). (B) Cartoon representations showing results of docking simulation of resveratrol to ligand-free
PIM-1 with stabilization energy of −7.9 kcal/mol (Ba) and AMPPNP-bound PIM-1 with stabilization energy of −7.1 kcal/mol (Bb). Resveratrol bound to PIM-1 is
illustrated as a stick model with carbon and oxygen atoms in white and red, respectively. Amino acid residues at the ATP-binding pocket are shown in stick
representations with nitrogen and oxygen atoms coloured in blue and red, respectively. (For interpretation of the references to colour in this figure legend, the reader
is referred to the Web version of this article.)
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Although the structure of PIM-3 is not available, we presume that its
structure would be similar to the that of PIM-1, considering the high
sequence similarity. Therefore, we do not exclude the possibility of
resveratrol binding to these two other PIM isoforms, thereby inhibiting
their catalytic activities, especially by occupying the ATP binding
pocket. Results from our preliminary test tube kinase assay revealed
that resveratrol inhibits PIM-2 kinase activity to the extent equivalent
to that observed with PIM-1. However, the effect on PIM-3 activity was
much weaker (data not shown), Further studies will be necessary to
more precisely assess the comparative effects of resveratrol on the ki-
nase activities of PIM isozymes.
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